换一批PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers
第一作者：
Luo, Linjie
作者：
关键词
Clinical trialcombination therapyDNA damage repair (DDR)drug resistancegermline BRCA-mutationhigh-grade serous ovarian cancer (HGSOC)homologous recombination deficiency (HRD)niraparibolaparibpoly (ADP-ribose) polymerase (PARP) inhibitorpreclinical studysomatic BRCA-mutationtriple-negative breast cancer (TNBC)rucaparibtalazoparibveliparibpamiparibfluzoparibimmunotherapyHOMOLOGOUS RECOMBINATION REPAIRTUMOR-INFILTRATING LYMPHOCYTESDNA-REPAIRPHASE-IIISYNTHETIC LETHALITYNEOADJUVANT CHEMOTHERAPYNEXT-GENERATIONEND RESECTIONOLAPARIBCARBOPLATIN
发布时间
2022-09-30
- 浏览1
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
